Full Length Research Paper
References
|
Abrescia N, D'Abbraccio M, Figoni M, Busto A, Butrico E, Marco MD, Viglietti R (2002). Fulminant hepatic failure after the start of an efavirenz-based HAART regimen in a treatment-naive female AIDS patient without hepatitis virus co-infection. Journal Antimicrobial Chemotherapy 50(5):763-765. |
|
|
Achonduh OA, AtoghoTB, Mbulli IA, Chedjou JP, Achu M, Nji AM, Fokou E, Kamgue E, Veyee V, Karana O, Sahfe D, Mbacham WF (2013). Adverse events clustering with NAT2 slow metabolisers following deparasitization in children in Bangolan, NWR Cameroon. Journal of Life Science 7(7):742-748. |
|
|
An HR, Wu XQ, Wang ZY, Zhang JX, Liang Y (2012). NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients. Clinical and Experimental Pharmacology and Physiology 39(6):535-543. |
|
|
Assam-Assam JP, Beng VP, Cho-Ngwa F, Tedom JC, Anyangwe AI, Titanji VPK (2011). Mycobacterium tuberculosis complex drug resistance pattern and identification of species causing tuberculosis in the West and Center regions of Cameroon. BMC Infectious Diseases 11(1):1-6. |
|
|
Ben Mahmoud L, Ghozzi H, Kamoun A, Hakim A, Hachicha H, Hammami S, Sahoung Z, Zalila N, Makmih H, Zeghal K (2012). Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity 364 in Tunisian patients with tuberculosis. Pathologie Biologie 60(5):324-330. |
|
|
Ben-Fredj N, Gam R, Kerkni E, Chaabane A, Chadly Z, Boughattas N, Aouam K (2016). Risk factors of isoniazid-induced hepatotoxicity in Tunisian tuberculosis patients. Pharmacogenomics Journal 17(4):372-377. |
|
|
Blum M, Demierre A, Grant DM, Heim M, Meyer UA (1991). Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proceedings of the National Academy of Sciences of the United States of America 88(12):5237-5241. |
|
|
Colebunders R, Lambert ML (2002). Management of co-infection with HIV and TB: improving tuberculosis control programmes and access to highly active antiretroviral treatment is crucial. British Medical Journal 342(7341):802-803. |
|
|
Demographic and Health Survey and with Multiple Indicators (2011). |
|
|
Desta Z, Saussele T, Ward B, Blievernicht J, Lang L, Klein K, Flockhart D, Zanger UM (2007). Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics 8(6):547-558. |
|
|
Gollub EL, Trino R, Salmon M, Moore L, Dean JL, Davidson BL (1997). Co-occurrence of AIDS and tuberculosis: results of a database "match" and investigation. Journal of Acquired Immune Deficiency Syndromes 16(1):44-49. |
|
|
Havlir DV, Barnes PF (1999). Tuberculosis in Patients with Human Immunodeficiency Virus Infection. New England Journal of Medicine 340:367-373. |
|
|
Hyun JC, Won JK, Yon JR, Chang SK, Myung HN, Jong WK, Soo Y (2007). Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis 87(6):551-556. |
|
|
Kengne CJP, Akindeh MN, Innocent MA, Achonduh OA, Ekollo MA, Mbacham WF (2016). Predominance of N-acetyl transferase 2 slow acetylator alleles in children less than ten years experiencing adverse treatment events following artemisinin-based combination therapy in North and South West Regions of Cameroon. African Journal of Biotechnology 15(25):1285-1291. |
|
|
Khalili H, Fouladdel S, Sistanizad M, Hajiabdolbaghi M, Azizi E (2011). Association of N-Acetyltransferase-2 Genotypes and Anti-Tuberculosis Induced Liver Injury; First Case-Controlled Study from Iran. Current Drug Safety 6(1):17-22. |
|
|
Lee SW, Chung LS, Huang HH, Chuang TY, Liou YH, Wu LS (2010). NAT2 and CYP 2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. International Journal of Tuberculosis and Lung Diseases 14(5):622-626. |
|
|
Leiro-Fernandez V, Valverde DX, Vázquez-Gallardo K, Botana-Rial M, Constenla L, Agúndez JA, Fernández-Villar A (2011). N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians. International Journal of Tuberculosis and Lung Diseases 15(10):1403-1408. |
|
|
Margulis SJ, Honig CL, Soave R, Govoni AF, Mouradian JA (1986). Biliary Tract Obstruction in the Acquired Immunodeficiency Syndrome. Annals of Internal Medicine 105(2):207-210. |
|
|
Mariz CA, Albuquerque MFPM, Lopes EP, Ximenes RAA, Lacerda HA, Filho DBM, Martins BBC, Pastor AFP, Santos BA (2020). Hepatotoxicity during TB treatment in people with HIV/AIDS related to NAT2 polymorphisms in Pernambuco, Northeast Brazil. Annals of Hepatology 19(2):153-160. |
|
|
Mc Donagh EM, Boukouvala S, Aklillu E, Hein DW, Altman RB, Klein TE (2014). PharmGKB summary: very important pharmacogene information for N acetyltransferase 2. Pharmacogenetics and Genomics 24(8):409-425. |
|
|
NTCP (2012). Epidemiological situation of tuberculosis in Cameroon. |
|
|
NTCP (2019). Epidemiological situation of tuberculosis in Cameroon. |
|
|
Oluwafemi O, Oguntibeju B, Olatubosan B (2003). A Study on the Activities of Liver Enzymes in HIV/ AIDS Patients. Journal of Medicine and Science 3:106-109. |
|
|
Pan L, Jia ZS, Chen L, Fu EQ, Li GY (2005). Effect of anti-tuberculosis therapy on liver function of pulmonary tuberculosis patients infected with hepatitis B virus. World Journal of Gastroenterology 11(16):2518-2521. |
|
|
Raghu R, Karthikeyan S (2016). Zidovudine and isoniazid induced liver toxicity and oxidative stress: evaluation of mitigating properties of silibinin. Environmental Toxicology and Pharmacology 46:217-226. |
|
|
Sadaphal JP, Astemborski NM, Graham, Sheely L, Bonds M, Madison A, Vlahov D, Thomas DL, Sterling TR (2001). Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis. Clinical Infectious Diseases 33(10):1687-1691. |
|
|
Sama LF, Nganou-Djinou OI, Wam EC, Bamou R, Ali IM, Noubom M, Tume CB (2017). Sero-prevalence of Hepatitis B and C virus and High Risk of Hepatotoxicity among TB / HIV Positive and HIV Negative Population in Western Cameroon. Global Journal of Infectious Diseases 3(1):001-008. |
|
|
Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin PM, Nunes D, Strader DB, Bernardo J, Venkataramanan R, Sterling TR (2006). An official ATS statement: hepatotoxicity of antituberculosis therapy. American Journal of Respiratory and Critical Care Medicine 174(8):935-952. |
|
|
Schechter M, Zajdenverg R, Falco G, Barnes GL, Faulhaber JC, Coberly JS, Moore RD, Chaisson RE (2006). Weekly rifapentine / isoniazid or daily rifampin / pyrazinamide for latent tuberculosis in household contacts. American Journal of Respiratory and Critical Care Medicine 173(8):922-926. |
|
|
Sidze LK, Mouafo TE, Kuaban C, Assam Assam JP, Tedom JC, Eyangoh S, Fouda FX, Nolna D, Ntoumi F, Frank M, Beng VNP (2014). Strong Decrease in Streptomycin-Resistance and Absence of XDR 12 Years after the Reorganization of the National Tuberculosis Control Program in the Central Region of Cameroon. Plos One 9(6):e98374. |
|
|
Soukaina G, Ilham R, Fatima ZL, Siham CE, Imane CJ, Amina B, Abdelaziz S (2014). Distribution of allelic and genotypic frequencies of NAT2and CYP2E1variants in Moroccan population. BMC Genetics 15(1):1-6. |
|
|
Soukaina G, Ilham R, Omaima El Bouazzi, Sanaa H, Amina T, Jamal EB, Rachida SB, and Abdelaziz S (2016). NAT2 Genotypes in Moroccan Patients with Hepatotoxicity Due to Antituberculosis Drugs. Genetic Testing and Molecular Biomarkers 20(11):680-684. |
|
|
Sun F, Chen Y, Xiang Y, Zhan S (2008). Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis. International Journal of Tuberculosis and Lung Diseases. 12(9):994-1002. |
|
|
Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R (2008). Antituberculosis drug-induced hepatotoxicity: concise up -to-date review. Journal of Gastroenterology and Hepatology 23(2):192-202. |
|
|
Van Hest R, Baars H, Kik S, van Gerven P, Trompenaars MC, Kalisvaard N, Keizer S, Borgdorff M, Mensen M, Cobelens F (2004). Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. Clinical Infectious Diseases 39(4):488-496. |
|
|
Wares DF, Singh S, Acharya AK, Dangi R (2003). Non-adherence to tuberculosis treatment in the eastern Tarai of Nepal. International Journal of Tuberculosis and Lung Disease 7(4):327-335. |
|
|
Wild-Up M, Fortuin F, Whittle DHC, Hall AJ, Wolf CR, Montesonai R (1990). Liver and hepatitis B virus in Gambian children. Cancer Epidemiology, Biomarkers and Preventions 2:555-561. |
|
|
World Health Organization (2012). Library Cataloguing-in-Publication Data: Treatment of tuberculosis: guidelines - 4th edition. (accessed 28 May 2012).WHO/HTM/TB/2009.420. |
|
|
World Health Organization (2018). Global tuberculosis report 2018. Geneva (Switzerland). |
|
|
World Health Organization (2019). Global tuberculosis report 2019. Geneva (Switzerland). |
|
|
Yang JJ, Huang CH, Liu CE, Tang HJ, Yang CJ, Lee YC, Lee KY, Tsai MS, Lin SW, Chen YH, Lu PL, Hung CC (2014). Multicenter study of trimethoprim/sulfamethoxazole related hepatotoxicity: incidence and associated factors among HIV-infected patients treated for Pneumocystis jirovecii pneumonia. PloS One 9(9):e106141. |
|
|
Yimer G, Ueda N, Habtewold A, Amogne W, Suda A, Kiedel KD, Burhenne J, Aderaye G, Lindquist L, Mkonnen E, Aklillu E (2011). Pharmacogenetic and Pharmacokinetic Biomarker for Efavirenz Based ARV and Rifampicin Based Anti-TB Drug Induced Liver Injury in TB-HIV Infected Patients. PloS One 6(12):e27810. |
|
|
Younossian AB, Rochat T, Ketterer JP, Wacker J, Janssens JP (2005). High hepatotoxicity of pyrazinamide and ethambutolfor treatment of latent tuberculosis. European Respiratory Journal 26(3):462-464. |
|
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
